Study on Internet Medical Models for the Management of Patients With Hypertension in China
NCT03527563
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
13901333060
1. Male or female, 45 to 75 years old (including 45 and 75 years);
2. Two measurements of resting systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg on different days during screening;
3. Female subjects of child-bearing potential who are willing to adopt one of the following methods for contraception during the study:
Oral contraceptive, either combined or progestogen alone. Injectable progestogen. Implants of levonorgestrel. Oestrogenic vaginal ring. Percutaneous contraceptive patches. Intrauterine device or intrauterine system showing that the expected failure rate is less than 1% per year as stated in the product label.
Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
4. Subjects who can understand and perform home blood pressure monitoring as required by the study;
5. Subjects who voluntarily participate in the study and sign informed consent form.
1. Two measurements of resting systolic blood pressure ≥180mmHg and/or diastolic blood
pressure ≥110mmHg on different days during screening;
2. Subjects with the history of cerebral stroke within 6 months prior to screening;
3. Subjects with the history of myocardial infarction within 6 months prior to screening;
4. Subjects with the history of heart failure;
5. Subjects with the history of atrial fibrillation;
6. Subjects with the history of coronary artery revascularization;
7. Subjects with other serious diseases, such as tumor;
8. Subjects diagnosed as the secondary hypertension;
9. Subjects with congenital or acquired organic heart disease;
10. Pregnant or lactant subjects;
11. Subjects with severe mental disease;
12. Subjects with abnormal liver and renal function: ALT or AST>2 X upper limit value; Or
creatinine >2 X upper limit value;
13. Subjects who were previously diagnosed with diabetes that is currently poorly
controlled: FBG>10mmol/L;
14. Subjects who are unable to conduct blood pressure self-test;
15. The subject has any other known condition at screening that would compromise subject
safety, might affect life expectancy, or making it difficult to successfully manage
and follow the subject according to the protocol.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Laval, Quebec
- E. Hanover, New Jersey
- London, Ontario
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title ICMJE | Study on Internet Medical Models for the Management of Patients With Hypertension in China | ||||
Official Title ICMJE | A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients With Hypertension in China | ||||
Brief Summary | The study is a multi-center, randomized, open, and parallel study. Approximately 958 subjects will be enrolled in 16 sites. The random number table will be adopted to conduct cluster randomization per township hospital/community health service center. Patients will be randomized 1:1 to receive blood pressure management in Internet medical model or Conventional medical model. After follow-ups of 3 months and 6 months, the blood pressure in each group will be observed and compared. | ||||
Detailed Description | Protocol Title?A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients with Hypertension in China Study Indication:Hypertension Number of Site:16sites Study Duration (from the initiation of the first site to the end of the follow-up for the last subject): 12 months Duration of Treatment and Management: 6 months Planned Number of Subjects:958 subjects, 479 in each group(blood pressure management in Internet medical model, Conventional medical model) Internet Medical Model:Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment. Conventional Medical Model:Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment. Inclusion Criteria?
Exclusion Criteria?
Efficacy Evaluations? Primary Efficacy Endpoints:
| ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Not Applicable | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: The study is a multi-center, randomized, open, and parallel study. Approximately 958 subjects will be enrolled in 16 sites. The random number table will be adopted to conduct cluster randomization per township hospital/community health service center. Patients will be randomized 1:1 to receive blood pressure management in Internet medical model or Conventional medical model. After follow-ups of 3 months and 6 months, the blood pressure in each group will be observed and compared Masking: None (Open Label)Primary Purpose: Other | ||||
Condition ICMJE | Hypertension | ||||
Intervention ICMJE | Behavioral: Internet Medical Model
Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ? 180mmHg or ? 100mmHg and diastolic blood pressure ? 110mmHg or ? 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry. | ||||
Study Arms ICMJE |
| ||||
Publications * |
| ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status ICMJE | Unknown status | ||||
Estimated Enrollment ICMJE | 958 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | December 2019 | ||||
Estimated Primary Completion Date | September 2019 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||
Sex/Gender ICMJE |
| ||||
Ages ICMJE | 45 Years to 75 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Not Provided | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03527563 | ||||
Other Study ID Numbers ICMJE | Not Provided | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
| ||||
IPD Sharing Statement ICMJE |
| ||||
Responsible Party | China Cardiovascular Association | ||||
Study Sponsor ICMJE | China Cardiovascular Association | ||||
Collaborators ICMJE | Pfizer | ||||
Investigators ICMJE |
| ||||
PRS Account | China Cardiovascular Association | ||||
Verification Date | January 2019 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |